Nazione: Stati Uniti
Lingua: inglese
Fonte: NLM (National Library of Medicine)
NICARDIPINE HYDROCHLORIDE (UNII: K5BC5011K3) (NICARDIPINE - UNII:CZ5312222S)
Sun Pharmaceutical Industries, Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, transfer patients to oral medication as soon as their clinical condition permits [see Dosage and Administration (2.1) ]. Nicardipine hydrochloride injection is contraindicated in patients with advanced aortic stenosis because part of the effect of nicardipine hydrochloride injection is secondary to reduced afterload. Reduction of diastolic pressure in these patients may worsen rather than improve myocardial oxygen balance. Pregnancy Category C There are no adequate and well-controlled studies of nicardipine use in pregnant women. However, limited human data in pregnant women with preeclampsia or pre-term labor are available. In animal studies, no embryotoxicity occurred in rats with oral doses 8 times the maximum recommended human dose (MRHD) based on body surface area (mg/m2 ), but did occur in rabbits with oral doses at 24
Nicardipine hydrochloride injection is available in packages of 10 ampuls of 10 mL as follows: 25 mg/10 mL (2.5 mg/mL) NDC 47335-882-44 Store at 20° to 25° C (68° to 77° F); excursions permitted between 15° and 30°C (59° and 86°F). [See USP Controlled Room Temperature]. Freezing does not adversely affect the product, but avoid exposure to elevated temperatures. Protect from light. Store ampuls in carton until used. Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway, Halol-389350, Gujarat, India. PJPI0551 ISS. 02/2021
New Drug Application
NICARDIPINE HYDROCHLORIDE - NICARDIPINE HYDROCHLORIDE INJECTION SUN PHARMACEUTICAL INDUSTRIES, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE NICARDIPINE HYDROCHLORIDE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NICARDIPINE HYDROCHLORIDE INJECTION. NICARDIPINE HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1988 INDICATIONS AND USAGE Nicardipine hydrochloride injection is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.(1.1) DOSAGE AND ADMINISTRATION For Intravenous Use. (2.1) Dilution is required. (2.3) When substituting for oral nicardipine therapy, use the intravenous infusion rate from the table below (2.1): ORAL NICARDIPINE DOSE EQUIVALENT I.V. INFUSION RATE (0.1 MG/ML) 20 mg q8h 0.5 mg/hr = 5 mL/hr 30 mg q8h 1.2 mg/hr = 12 mL/hr 40 mg q8h 2.2 mg/hr = 22 mL/hr In a patient not receiving oral nicardipine, initiate therapy at 50 mL/hr (5 mg/hr) 0.1 mg/mL solution. Increase the infusion rate by 25 mL/hr every 5 minutes (for rapid titration) to 15 minutes (for gradual titration) up to a maximum of 150 mL/hr until desired blood pressure reduction is achieved. (2.1) If unacceptable hypotension or tachycardia occurs, discontinue the infusion. When blood pressure and heart rate stabilize, restart the infusion at low doses such as 30 to 50 mL/hr. (2.2) DOSAGE FORMS AND STRENGTHS Nicardipine hydrochloride injection is supplied in an ampul containing 25 mg of nicardipine hydrochloride in 10 mL (2.5 mg/mL) for intravenous infusion. (3) CONTRAINDICATIONS Do not use in patients with advanced aortic stenosis (4.1). WARNINGS AND PRECAUTIONS Closely monitor response in patients with angina, heart failure, impaired hepatic function, or renal impairment. (5.1, 5.2, 5.3, 5.4) To reduce the possibility of venous thrombosis, phlebitis, and vascular impairment, do not use small veins, such as those on the dorsum of the hand or wrist. Exercise extr Leggi il documento completo